ProcartaPlex™ Human Cytokine Panel 1B, 25plex
ProcartaPlex™ Human Cytokine Panel 1B, 25plex
Invitrogen™

ProcartaPlex™ Human Cytokine Panel 1B, 25plex

El panel 1B ProcartaPlex 25-Plex de citocina de especie humana permite la investigación de la función inmunitaria mediante el análisisMás información
Have Questions?
Número de catálogoCantidad
EPX250-12166-90196 pruebas
Número de catálogo EPX250-12166-901
Precio (USD)
-
Cantidad:
96 pruebas
El panel 1B ProcartaPlex 25-Plex de citocina de especie humana permite la investigación de la función inmunitaria mediante el análisis de 25 proteínas diana en un solo pocillo a través de la tecnología Luminex xMAP. El panel se compone de tres subpaneles modulares que son un subconjunto del panel 1 ProcartaPlex 45-Plex de citocina/quimiocina/factores de crecimiento (n.º de ref. EPX450-12171-901). Este kit es totalmente combinable con los otros subpaneles o ensayos individuales simples correspondientes a los objetivos del panel de 45 plex.

Los paneles preconfigurados ProcartaPlex se han probado exhaustivamente para determinar la capacidad combinatoria, la interferencia y la reactividad cruzada de los analitos con el fin de proporcionar el mayor nivel de validación y precisión. Todos los paneles ProcartaPlex se suministran con los reactivos necesarios para realizar el ensayo.

Los paneles multiplex ProcartaPlex están disponibles en múltiples formatos en seis especies (humano, ratón, rata, primate no humano, porcino y canino). Visite nuestra página de inmunoensayos ProcartaPlex para obtener más información y consultar los productos disponibles.

Lista de objetivos [región de gránulos]:
Th1/Th2: GM-CSF [44], IFN gamma [43], IL-1 beta [18], IL-2 [19], IL-4 [20], IL-5 [21], IL-6 [25], IL-12p70 [34], IL-13 [35], IL-18 [66], TNF alfa [45]
Th9/Th17/Th22/Treg: IL-9 [52], IL-10 [28], IL-17A (CTLA-8) [36], IL-21 [72], IL-22 [76], IL-23 [63], IL-27 [14]
Citocinas inflamatorias: IFN alfa [48], IL-1 alfa [62], IL-1RA [38], IL-7 [26], IL-15 [65], IL-31 [37], TNF beta [54]

Acerca de los ensayos ProcartaPlex para la plataforma Luminex
Los inmunoensayos ProcartaPlex se basan en los principios de un ELISA tipo sándwich y utilizan dos anticuerpos altamente específicos que se enlazan a los diferentes epítopos de una proteína para cuantificar todas las proteínas diana simultáneamente mediante un instrumento Luminex. Para los ensayos multiplex ProcartaPlex se requieren tan solo 25 µl de plasma o suero, o 50 µl de sobrenadante del cultivo celular, y solo se necesitan cuatro horas para obtener los resultados analizados.

Las características incluyen:
• Resultados reproducibles y fiables: validados como panel según el estándar más alto del sector, incluidas las pruebas de combinación de proteínas diana y reactividad cruzada
• Más resultados por muestra: permite medir múltiples proteínas diana simultáneamente en una única muestra de 25–50 µL
• Tecnología Luminex consolidada: plataforma de multiplexing de referencia para detección y cuantificación de proteínas

Los ensayos ProcartaPlex utilizan la tecnología Luminex xMAP (método multianálito) para la detección y cuantificación simultáneas de hasta 65 proteínas diana en una única muestra de 25–50 µL de plasma, suero, sobrenadantes del cultivo celular y otros fluidos corporales.

Las microesferas de Luminex del ensayo de ProcartaPlex se tiñen internamente con proporciones precisas de fluoróforos rojos e infrarrojos para crear firmas específicas que pueden ser identificadas por los sistemas de detección Luminex xMAP (por ejemplo, Luminex 200, FLEXMAP 3D y MAGPIX). El ensayo ProcartaPlex, similar a un ELISA tipo sándwich, utiliza pares de anticuerpos emparejados para identificar la proteína de interés. En un ensayo multiplex, cada gránulo espectralmente único se etiqueta con anticuerpos específicos para una sola proteína diana, y las proteínas vinculadas se identifican con anticuerpos biotinilados y estreptavidina-R-ficoeritrina (RPE). La conjugación de anticuerpos específicos de proteínas en un gránulo distinto permite el análisis de varios elementos diana en un solo pocillo.

La diferencia más significativa entre un ensayo ProcartaPlex y uno ELISA es que el anticuerpo de captura del ensayo ProcartaPlex se conjuga en un gránulo y no se adsorbe en el pocillo de la microplaca, por lo que los reactivos del ensayo ProcartaPlex flotan en la solución. Para la detección, el instrumento Luminex 200, por ejemplo, contiene dos láseres, uno para distinguir la firma espectral de cada partícula y el segundo para cuantificar la cantidad de fluorescencia RPE, que es proporcional a la cantidad de proteína presente en la muestra. Los ensayos multiplex ProcartaPlex pueden determinar el perfil de más proteínas diana con mucha menos muestra en el mismo tiempo que se tarda en realizar un ELISA tipo sándwich tradicional.

Los paneles multiplex ProcartaPlex están disponibles en múltiples formatos en seis especies (humano, ratón, rata, primate no humano, porcino y canino). Visite thermofisher.com/procartaplex para obtener más información y consultar los productos disponibles.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.
Especificaciones
Intervalo del ensayoVer certificado de análisis
Sensibilidad del ensayoMenos del 15 %
Para utilizar con (equipo)Instrumentos Luminex™
FormatoKit multiplex
Línea de productosProcartaPlex
Tipo de muestraSobrenadantes de cultivo celular, suero y plasma, Plasma, Cell Culture Supernatants
Volumen de muestraSuero, plasma: 25 μl; CCS: 50 μl
Condiciones de envíoHielo húmedo
CombinabilityCombinable
Tipo de productoPanel
Cantidad96 pruebas
Research AreaImmunology, Cytokines
EspecieHumano
Unit SizeEach
Contenido y almacenamiento
  • 2 viales de mezcla estándar humana A (liofilizada)
  • 2 viales de mezcla estándar humana B (liofilizada)
  • 1 vial de mezcla de gránulos de captura B (1X)
  • 1 vial de mezcla de gránulos de captura C (1X)
  • 1 vial de mezcla de gránulos de captura D (1X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada B (50X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada C (50X)
  • 1 vial de mezcla de anticuerpos de detección biotinilada D (50X)
  • 1 frasco de tampón de lectura (1X)
  • 1 frasco de tampón de lavado (10x)
  • 1 frasco de estreptavidina-PE (1X)
  • 1 frasco de tampón de ensayo universal (1 X)
  • 1 frasco de diluyente de anticuerpos de detección (1X)
  • Tira de 8 tubos
  • Película adhesiva
  • Placa de 96 pocillos de fondo plano, negra

Preguntas frecuentes

What is the size of the Luminex beads you currently use?

The beads used in our Luminex instrument-compatible ProcartaPlex and QuantiGene Plex assays are 6.5 micron superparamagnetic beads.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

I am interested in performing Luminex assays using BioSource kits, and I have a Luminex xMAP system. Besides the kits and system, what other reagents and equipment will I need?

The following is a list of general lab supplies that are required for running BioSource immunoassays on the Luminex xMAP system:
1) Sonicating water bath
2) Orbital shaker
3) Vortexer
4) Repeating and/or multi-channel pipetter (not required, but recommended)
5) Calibrated adjustable precision pipettes, with disposable plastic tips
6) Glass/plastic tubes and racks for preparing reagents
7) Graduated cylinder and container for preparing wash solution
8) Aluminum foil
9) Deionized or distilled water.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Do the Luminex beads require special care in handling?

The Luminex beads should be protected from light because they are susceptible to photobleaching. We recommend protecting the beads by keeping containers covered with aluminum foil during all incubation steps, and exercising care during handling. The beads should not be frozen, subjected to excessive heat, or exposed to organic solvents.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Why would the Luminex acquisition software display "Sample Empty" messages during analysis?

(1) The user did not properly aliquot the diluted beads, such that no beads were actually added to the wells (make sure that the bead concentrates are sonicated and vortexed well, then check the pipet tip to ensure that air bubbles were not drawn up)
(2) The user missed loading diluted beads to some wells, which is likely since the small volume is clear and difficult to visualize in the clear plastic plate (we have now addressed this customer difficulty by coloring each of the Buffer Reagent Kit components)
(3) The user applied too much vacuum pressure at some point during the wash steps, or allowed the pressure to spike even once, such that the filter membrane tore in a few wells releasing the beads (make sure that the vacuum manifold pressure is kept below 5mm/in Hg, depending on their system -- a good rule of thumb is that it should take a full 3-second count to GENTLY empty the wells of 200uL)
(4) The user did not properly sonicate and vortex the beads prior to dilution, such that the percent of bead aggregation was high and the instrument was unable to find enough single beads to meet the events/bead value designated by the customer (make sure that the Bead Concentrate tube is put into the waterbath all the way to the cap, since the tube is hollow until the top third)
(5) The user lost beads by shaking the plate too aggressively or handling it improperly (make sure that the orbital shaker is set to a speed that allows for maximum vortex in the wells without spillage)
(6) The user exposed the beads to an excess of light during storage or running of the assay, such that some but not all of the beads were photobleached and therefore falling outside the acceptable range for each bead region (make sure that the plate is covered on the top/sides with foil throughout the assay, away from Windows and spotlights, and that the bead component of the kits is stored in the dark)*
(7) There was a clog in the sample needle, such that the instrument was unable to take up enough sample to meet the number of events requested per bead region (suggest that the user follow the manual instructions for dislodging a clog, which include several Back Flush steps and may require removal of the needle for sonication with probe alignment).

* Some of the older Antibody Bead Kits still have clear plastic tops instead of black ones. In cases where customers store kits in lit refrigerators, or keep them open on the lab bench, even a few hours of light exposure is enough to photobleach beads. It is important to note, in general, that higher number bead regions are more susceptible to photobleaching. In order to draw conclusions about the source of the difficulty, we would ask to see the data, specifically the Masterplex QT file, which would enable us to examine the pattern of "Sample Empty" occurrences in addition to the bead counts per well.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

What are the Luminex beads made of?

The beads are made of polystyrene.

Find additional tips, troubleshooting help, and resources within our Protein Assays and Analysis Support Center.

Citations & References (8)

Citations & References
Abstract
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Authors:Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, Bopp B, Lang F, Zang T, Kröger T, Ernst T, Kögler G, Krieg A, Lüdeke S, Kunkel H, Rodrigues Moita AJ, Kassack MU, Marquardt V, Opitz FV, Oldenburg M, Remke M, Babor F, Grez M, Hochhaus A, Borkhardt A, Groth G, Nagel-Steger L, Jose J, Kurz T, Gohlke H, Hansen FK, Hauer J
Journal:Blood
PubMed ID:29724897
'Heat shock protein 90 (HSP90) stabilizes many client proteins, including the BCR-ABL1 oncoprotein. BCR-ABL1 is the hallmark of chronic myeloid leukemia (CML) in which treatment-free remission (TFR) is limited, with clinical and economic consequences. Thus, there is an urgent need for novel therapeutics that synergize with current treatment approaches. Several ... More
Reduced levels of cytosolic DNA sensor AIM2 are associated with impaired cytokine responses in healthy elderly.
Authors:Wang Q, Westra J, van der Geest KS, Moser J, Bijzet J, Kuiper T, Lorencetti PG, Joosten LA, Netea MG, Heeringa P, Brouwer E, Boots AM
Journal:Exp Gerontol
PubMed ID:26944367
Human aging is associated with remodeling of the immune system. While most studies on immunosenescence have focused on adaptive immunity, the effects of aging on innate immunity are not well understood. Here, we investigated whether aging affects cytokine responses to a wide range of well-defined pattern recognition receptor (PRR) ligands, ... More
Serum cytokine measurements and biological therapy of psoriasis - Prospects for personalized treatment?
Authors:Solberg SM, Sandvik LF, Eidsheim M, Jonsson R, Bryceson YT, Appel S
Journal:Scand J Immunol
PubMed ID:30307657
Psoriasis is an immune-mediated disease where the IL-23/Th17 axis as well as TNF comprise main targets of biological therapy. Immune profiling has so far not been embraced as a clinical tool. We aimed to investigate relationships between individual serum cytokine levels in 40 psoriasis patients before and after receiving biological ... More
Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector T
Authors:Chiang D, Chen X, Jones SM, Wood RA, Sicherer SH, Burks AW, Leung DYM, Agashe C, Grishin A, Dawson P, Davidson WF, Newman L, Sebra R, Merad M, Sampson HA, Losic B, Berin MC
Journal:J Allergy Clin Immunol
PubMed ID:29408715
The contribution of phenotypic variation of peanut-specific T cells to clinical allergy or tolerance to peanut is not well understood.
Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
Authors:Rotolo A, Caputo VS, Holubova M, Baxan N, Dubois O, Chaudhry MS, Xiao X, Goudevenou K, Pitcher DS, Petevi K, Kachramanoglou C, Iles S, Naresh K, Maher J, Karadimitris A
Journal:Cancer Cell
PubMed ID:30300581
Chimeric antigen receptor anti-CD19 (CAR19)-T cell immunotherapy-induced clinical remissions in CD19